Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Champlin
Richard E
RE
University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Kantarjian
Hagop
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019496:Cancer Vaccines; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D018365:Neoplasm, Residual; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate